From Pan-Reactive Kv7 Channel Opener to Subtype Selective Opener/Inhibitor by Addition of a Methyl Group

Sigrid Marie Blom1,3,a, Mario Rottländer2,3,b, Jan Kehler2, Christoffer Bundgaard3, Nicole Schmitt3, Henrik Sindal Jensen1,a

1 Division of Neuroscience Drug Discovery, H. Lundbeck A/S, Copenhagen, Denmark, 2 Division of Discovery Chemistry and DMPK, H. Lundbeck A/S, Copenhagen, Denmark, 3 Department of Biomedical Sciences and Danish National Research Foundation Centre for Cardiac Arrhythmia, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Abstract

The voltage-gated potassium channels of the Kv7 family (Kv7.1–5) play important roles in controlling neuronal excitability and are therefore attractive targets for treatment of CNS disorders linked to hyperexcitability. One of the main challenges in developing Kv7 channel active drugs has been to identify compounds capable of discriminating between the neuronally expressed subtypes (Kv7.2–5), aiding the identification of the subunit composition of Kv7 currents in various tissues, and possessing better therapeutic potential for particular indications. By taking advantage of the structure-activity relationship of acrylamide Kv7 channel openers and the effects of these compounds on mutant Kv7 channels, we have designed and synthesized a novel Kv7 channel modulator with a unique profile. The compound, named SMB-1, is an inhibitor of Kv7.2 and an activator of Kv7.4. SMB-1 inhibits Kv7.2 by reducing the current amplitude and increasing the time constant for the slow deactivation kinetics. The activation of Kv7.4 is seen as an increase in the current amplitude and a slowing of the deactivation kinetics. Experiments studying mutant channels with a compromised binding site for the Kv7.2–5 opener retigabine indicate that SMB-1 binds within the same pocket as retigabine for both inhibition of Kv7.2 and activation of Kv7.4. SMB-1 may serve as a valuable tool for Kv7 channel research and may be used as a template for further design of better subtype selective Kv7 channel modulators. A compound with this profile could hold novel therapeutic potential such as the treatment of both positive and cognitive symptoms in schizophrenia.

Introduction

The neuronally expressed members of the Kv7 family (Kv7.2–5) are the molecular correlates of the M-current, a slowly activating and slowly deactivating potassium current [1,2,3]. Kv7 channels open at voltages below the threshold required for generation of an action potential and play a fundamental role in the control of neuronal excitability. Accordingly, mutations in the genes encoding Kv7.2 and Kv7.3 result in a form of neonatal epilepsy [4,5,6]. Hence, drugs that increase the activity of Kv7 channels have a great therapeutic potential for the treatment of diseases characterized by hyperexcitability, such as epilepsy and neuropathic pain. Retigabine (Trobalt/Potiga), which activates Kv7.2–5, was approved as an add-on treatment for partial onset seizures in 2011 and has proven effective in preclinical models for a wide variety of diseases [7,8,9,10].

Based on mutation studies, retigabine has been shown to bind to a hydrophobic pocket between transmembrane segments 5 and 6 of the channel proteins. Specifically, channel activation by retigabine is critically dependent on a tryptophan residue (W236 in Kv7.2) in the cytoplasmic part of S5 [11,12]. The cardiac Kv7.1 channel has a leucine at this position explaining its resistance to retigabine-induced enhancement. It appears that the tryptophan residue constitutes a structural element of a promiscuous binding site in the channels, since compounds which are structurally different from retigabine, like BMS-204352, (S)-1 and (S)-2 also lose their activating effects when the tryptophan is substituted for a leucine [13,14]. Yet, compounds like ZnPy [15], ICA-27243 [16,17] and fenamic acids [18] are not dependent on its integrity, suggesting that other activator binding sites exist. A leucine within the pore loop and a leucine extending from S6 of the adjacent subunit have also been found to be important residues for retigabine sensitivity [19]. These residues are conserved between the neuronal subtypes whereas Kv7.1 carries valines in both positions. Introduction of the three critical residues in Kv7.1 confers full retigabine sensitivity [19].
We have previously shown that the acrylamide (S)-2 (fig. 1A) activates Kv7.2-5 [14]. For Kv7.4 and Kv7.5 the effect of (S)-2 is purely positive, while the compound has a bimodal effect on homeric Kv7.2 and heteromeric Kv7.2/3 channels. For Kv7.2, the positive effects of (S)-2 are a hyperpolarizing shift in the voltage-dependence of activation, a slowing of the deactivation kinetics (\(t_{\text{act,slow}}\)) and an acceleration of the fast component of the activation kinetics (\(t_{\text{act,fast}}\)). At voltages below \(-10\) mV the compound also increases the current amplitude and accelerates the slow component of the activation kinetics (\(t_{\text{act,slow}}\)). However, at voltages above \(-10\) mV the compound has a secondary inhibitory effect. At these depolarized voltages the effect on the current amplitude and \(t_{\text{act,slow}}\) crosses over and becomes inhibitory. When we tested (S)-2 on a mutated Kv7.2 channel where the tryptophan residue in S5 (which is essential for the effect of retigabine) was substituted for a leucine (KV7.2-W236L) all inhibitory. When we tested (S)-2 on a mutated Kv7.2 channel where the tryptophan residue in S5 (which is essential for the effect of retigabine) was substituted for a leucine (KV7.2-W236L) all activating effects of (S)-2 were lost and the compound became purely inhibitory. Based on these observations we proposed that the mechanism behind the inhibitory effect on Kv7.2-W236L and the secondary inhibitory action at the WT Kv7.2 may be the same and that the effect of (S)-2 on Kv7.2 can be divided into two entities: 1) an activating part visible as a shift in the voltage-dependence of activation and 2) an inhibitory part visible as a decrease in the current amplitude and an increase in \(t_{\text{act,slow}}\). According to this proposal, the interpretation of the experimental data is that the W236L mutation disables only the (S)-2 induced activation and thereby unmasks the inhibitory component of the drug effect. Consistent with this proposal is the observation that for Kv7.4, where the effect of (S)-2 is purely positive, the retigabine insensitive mutant (Kv7.4-W242L) is fully insensitive to (S)-2. This raised the question of whether it would be possible to design a compound that mimics the effect of the W-L mutation, resulting in an inhibitor of Kv7.2 that would not affect Kv7.4. Interestingly, it is described in the structure-activity-relationship of the acrylamide class of compounds that methylation of the amide nitrogen of a related acrylamide Kv7.2 opener (S)-1 results in a compound that inhibits Kv7.2 [20]. In our hands (S)-1 is also an inhibitor of Kv7.2-W236L (unpublished observation) and has been reported to be an inhibitor of Kv7.4-W242L [13]. We hypothesized that this chemical modification of the acrylamide may have the same effect as the W-L mutation where the methylated version of (S)-2 and (S)-1 would be an inhibitor of both Kv7.2 and Kv7.4, while the methylated version of (S)-2 would inhibit Kv7.2 but not Kv7.4. Here we describe the synthesis and characterization of an analogue of (S)-2, termed SMB-1, where the amide nitrogen is methylated (fig. 1B). We show that SMB-1 is indeed an inhibitor of Kv7.2. In contrast, Kv7.4 is activated by SMB-1. However, SMB-1 does not have sufficient penetration into the rodent brain to allow examination of its in vivo CNS profile.

**Materials and Methods**

**Molecular biology**

Point mutations were introduced using mutated oligonucleotide extension (PfuTurbo Polymerase, Stratagene, La Jolla, CA, USA) from a plasmid template harboring the cDNA of interest, digested with DpnI (Fermentas, St. Leon-Roth, Germany) and transformed into E.coli XL1 Blue cells. The construct was verified by complete DNA sequencing of the cDNA insert. cRNA was prepared from linearized human wild-type (WT) and mutant Kv7 channels in the pGEM-HE vector using the T7 m-Message Machine kit (Ambion, Austin, TX, USA) according to the manufacturer’s instructions.

**Electrophysiology**

Extraction of *Xenopus laevis* oocytes and injection of cRNA was performed as described previously [14]. Oocytes were kept in Modified Barth’s Saline (in mM: 88 NaCl, 1 KCl, 2.4 NaHCO3, 0.41 CaCl2, 0.82 MgSO4, 0.3 Ca(NO3)2, 15 HEPES, pH 7.4 supplemented with 100 U/mL penicillin and 100 μg/mL streptomycin) at 18°C, and currents were recorded after 2-7 days. The care of *Xenopus laevis* and the oocyte extraction procedure were performed according to national guidelines and approved by the Danish Animal Experiments Inspectorate.

Kv7 currents in *Xenopus laevis* oocytes were recorded using two-electrode voltage-clamp at room temperature in Ringer buffer (in mM: 115 NaCl, 2.5 KCl, 1.8 CaCl2, 0.1 MgCl2, 10 HEPES, pH 7.4) as described previously [14]. Data was acquired using pCLAMP 10.2 software (Molecular Devices, CA, USA) and analyzed using pCLAMP 10.2 and GraphPad Prism 4.0 (GraphPad Software Inc., CA, USA). Currents were elicited from a holding potential of \(-80\) mV by 5 s steps to potentials between \(-100\) and \(+50\) mV in 10 mV increments, followed by a 2 s step to \(-120\) mV.

SMB-1 was dissolved in dimethyl sulfoxide (DMSO) to obtain a concentrated stock solution. On the day of experiments the stock solution was thawed and diluted in Ringer buffer to the final concentrations. A concentration of 10 μM SMB-1 was used unless indicated otherwise. The final DMSO concentration never exceeded 0.1%.

**Curve fitting and statistical analysis**

Current – voltage (I-V) relationship curves were generated by normalizing the steady-state peak current measured at potentials between \(-100\) and \(+50\) mV to the current measured at \(+50\) mV in control recordings and plotting the values against the test potential. The voltage-dependence of activation was determined from tail current analysis using the current measured immediately after the transient capacitive current after stepping to \(-120\) mV from potentials between \(-100\) mV and \(+30\) mV. Data was normalized to extend from 0–1 and the tail current-voltage relationship was fitted to the Boltzmann equation:

\[
I(V) = \frac{I_{\text{max}} - I_{\text{min}}}{1 + \exp[(V - V_{0.5})/k]} + I_{\text{min}}
\]

where \(I_{\text{max}}\) is the maximum tail current, \(I_{\text{min}}\) is the minimum tail current, \(V_{0.5}\) is the potential for half maximal activation and \(k\) is the slope factor. A \(V_{0.5}\) was calculated for each individual experiment and statistical significance was estimated by paired two-tailed Student’s t-test.

Activation kinetics for Kv7.2 and Kv7.2-W236L was determined by fitting the traces recorded at potentials between \(-40\) and \(+40\) mV to a double exponential function:

\[
I(t) = I_{\text{fast}} \times \left(1 - \exp\left(-\frac{t}{\tau_{\text{fast}}}\right)\right)
+ I_{\text{slow}} \times \left(1 - \exp\left(-\frac{t}{\tau_{\text{slow}}}\right)\right)
\]

where \(I(t)\) is the current at time \(t\), \(I_{\text{fast}}\) and \(I_{\text{slow}}\) are the current amplitudes at infinite times, and \(\tau_{\text{fast}}\) and \(\tau_{\text{slow}}\) are the time constants of the fast and slow components, respectively.
and +50 mV to a single exponential function:

$$I(t) = I_0 \times \left(1 - \exp\left(-\frac{t}{\tau}\right)\right)$$  \hspace{1cm} (Equation 3)

where \(I(t)\) is the current at time \(t\), \(I_0\) is the peak current and \(\tau\) is the activation time constant.

For investigation of deactivation kinetics the tail current traces recorded at -120 mV when stepping from the channels’ respective \(V_{0.5}\) were fitted to a single exponential function (Eq. 3).

Dose-response curves from electrophysiological experiments were made by plotting the increase in steady state current at +50 mV expressed in percentages as a function of drug concentration. The data were then analyzed by non-linear regression and fitted to the equation for sigmoidal dose-response with variable slope:

$$Y = R_1 + \frac{R_2 - R_1}{1 + 10^{(\log EC_{50} - X) \times nH}}$$  \hspace{1cm} (Equation 4)

where \(R_1\) is the initial response, \(R_2\) is the maximum response, \(X\) is the logarithm of the drug concentration and \(nH\) is the slope (Hill coefficient) of the curve.

For data concerning activation kinetics statistical significance was determined by two-way ANOVA followed by Bonferroni post-test. Representative raw data were log-transformed before the statistical analysis to meet the assumption of normality. Statistical significance was determined by two-way repeated measurements ANOVA followed by Bonferroni post-test. Y-values were log-transformed before the statistical analysis to meet the assumption of normality. For traces fitted to double exponential functions only those where the sum of \(I_{fast}\) and \(I_{slow}\) equaled the peak current were included in the analysis.

For analysis of the remaining data statistical significance was determined by two-tailed Student’s t-test if single comparisons were made and by two-way ANOVA followed by Bonferroni post-tests if multiple comparisons were made. Statistical analyses were carried out using GraphPad Prism 4.0. \(p<0.05\) was accepted for statistical difference. All values are shown as mean ± S.E.M.

Rodent exposure studies

Ethical permission for the \textit{in vivo} rat procedures used in these studies was granted by the animal welfare committee, appointed by the Danish Ministry of Justice and all animal procedures were
carried out in compliance with EC Directive 86/609/EEC and with the Danish law regulating experiments on animals.

Brain and plasma exposure of SMB-1 was evaluated in male Sprague-Dawley rats (225–250 g, Charles River Lab., UK). SMB-1 was administered subcutaneously in solution at a dose of 20 mg/kg in 25% solutol (dose volume 5 ml/kg) and exposure was assessed after 30 and 120 min (n = 3). Under isoflurane anesthesia, cardiac blood was obtained in EDTA-coated tubes and centrifuged for 10 min at 4°C, after which plasma was harvested. While still under anesthesia, the animal was decapitated, the brain was removed and brain homogenate was prepared by homogenizing the whole brain with 70% acetone ([1:4 v/v]) followed by centrifugation and collection of the supernatant. Concentrations of SMB-1 were determined using turbolow chromatography (dual column, focus mode; Thermo Fisher Scientific, Waltham, MA) followed by tandem mass spectrometry detection (Sciex API-3000 MS; Applied Biosystems, Foster City, CA). The limit of detection was 1 ng/ml in plasma and 5 ng/g in brain.

Membrane permeability and free fraction determination

The bidirectional permeability (P_app) of SMB-1 was examined in an MDCK cell system expressing human MDR1 [ABCB1, P-glycoprotein (Pgp)] as described previously [21]. Permeation of the test compound from apical (A) to basal (B) direction or B to A direction was determined in triplicate over a 150-min incubation at 37°C. The efflux ratio was calculated as the ratio between P_app (B to A) and P_app (A to B). Free fraction of SMB-1 was determined using a standard equilibrium dialysis methodology with freshly isolated rat brain homogenate or plasma [22]. Equilibrium dialysis was performed by incubating at 37°C for 5 h in triplicates.

Chemistry

(S)-2 was prepared according to a literature procedure [23]. Synthesis of SMB-1 ((E)-N-[[(S)-1-(4-Cyclopropylmethyl-3,4-dihydro-2H-1,4-benzoxazin-6-(4-ethyl)-3-(2-fluoro-phenyl)-N-methylacyramide): To a solution of (S)-2 (100 mg, 262.8 μmol) in a mixture of anhydrous tetrahydrofuran (THF, 1.5 mL) and dimethylformamide (DMF, 0.5 mL) at 0°C was added NaH (16 mg, 394 μmol, 60% dispersion in mineral oil) and Mcl (17.8 μL, 289 μmol). The mixture was stirred at 0°C for four hours and at room temperature overnight. The mixture was cooled to 0°C, and diluted with ethylacetate (EtOAc, 10 mL). Water (10 mL) was added carefully, the organic phase was separated, and the aqueous layer was extracted by EtOAc. The combined organic layers were washed by brine, dried (NaSO₄), and concentrated to give SMB-1 (104 mg, yield: 100%) as an oil.

Application of 10 μM SMB-1 led to a reduction of current amplitudes at all activating potentials (fig. 1C and D). At +50 mV, the current amplitude was 81.7 ± 3.1% (n = 9) of control. A small, but significant, shift to more positive potentials was observed in the voltage-dependence of activation (V0.5: control: −22.5 ± 2.2 mV; SMB-1: −18.0 ± 2.7 mV, n = 9, p < 0.05, fig. 1E). We also assessed kinetic parameters by determining the time constants of deactivation (τ_deact) and activation (τ_act, fast and τ_act, slow). Deactivation kinetics were significantly slowed in the presence of SMB-1 (control: 20.2 ± 1.4 ms; SMB-1: 37.3 ± 3.3 ms, n = 7, p < 0.001, fig. 1F). SMB-1 did not affect τ_act, fast (fig. 1G) but increased τ_act, slow, at −20 mV and above (fig. 1H). These effects of SMB-1 are remarkably similar to the effect of (S)-2 on Kv7.2-W236L [14].

To determine the potency of SMB-1 on Kv7.2, the compound was tested at four concentrations (0.4, 2, 10 and 50 μM). Visual inspection of the solution indicated that the drug precipitated at concentrations above 50 μM. The current amplitude in percentage of control at +50 mV was plotted against the logarithm of the concentration. Fitting the data to the equation for sigmoidal dose-response with variable slope determined the EC50 value of SMB-1 to be 7.4 μM (pEC50: 5.1 ± 0.2 M, n = 5, fig. 1I). The compound was not able to fully inhibit the current within the concentration range tested, reaching a maximal inhibition of 67.6 ± 5.3% of control (n = 5) at +50 mV.

SMB-1 is an activator of Kv7.4

Next, we addressed the effect of SMB-1 on Kv7.4. Submitting Xenopus laevis oocytes expressing Kv7.4 channels to a voltage-step protocol elicited slowly activating currents. A representative experiment is shown in Figure 2A. Application of SMB-1 resulted in increased current amplitudes at −40 mV and above (fig. 2A and B). The current amplitude was 184.5 ± 12.4% of control (n = 8) at +50 mV in the presence of 10 μM SMB-1, which is low compared to the efficacy of (S)-2 on Kv7.4 (927% of control at +40 mV) [14]. SMB-1 did not affect the voltage-dependence of activation of Kv7.4 (fig. 2C, V0.5: control: −0.2 ± 3.6 mV; SMB-1: −1.4 ± 3.4 mV, n = 8, p = 0.59). Yet, 10 μM SMB-1 significantly increased τ_act, fast (control: 10.3 ± 0.6 ms; SMB-1: 16.4 ± 1.2 ms, n = 8, p < 0.001) and τ_act, slow at all potentials tested (fig. 2D). The EC50 value was determined to 5.7 μM (pEC50: 5.2 ± 0.4 M, n = 5) and the maximal efficacy to 217.7 ± 33.1% (n = 5) at +50 mV (fig. 2F).

Dependency on the critical tryptophan residue for inhibition/activation by SMB-1

to determine whether SMB-1 was dependent on the critical tryptophan residue in the ‘retigabine binding-site’ for its inhibitory/activating effects, the compound was applied to mutant channel proteins Kv7.2-W236L and Kv7.4-W242L (fig. 3 and 4). Kv7.2-W236L was inhibited by SMB-1 similar to wild-type (WT) Kv7.2 (fig. 3A and B). The current amplitude at +50 mV was 68.8 ± 3.9% of control (n = 6). We observed a trend towards an increase in the half-maximal value for voltage-dependence of activation V0.5 (control: −27.1 ± 2.4 mV; SMB-1: −15.0 ± 1.0 mV, n = 4, p = 0.2, fig. 3C). There was a small but significant increase in τ_deact (control: 23.3 ± 2.9 ms; SMB-1: 27.0 ± 3.0 ms, n = 6, p < 0.05, fig. 3D). Like for WT Kv7.2, there was no significant effect of SMB-1 on τ_act, fast (fig. 3E), while τ_act, slow was significantly increased at potentials above −20 mV (fig. 3F).

In contrast, the activating effect of SMB-1 on Kv7.4 was abolished in the W242L mutant channel; the mutant channel was inhibited by the compound (fig. 4A and B). The current amplitude was 74.8 ± 2.2% of control (n = 5) at +50 mV. At 10 μM, SMB-1 did not affect the voltage-dependence of activation (control: V0.5: 5.5 ± 4.5 mV; SMB-1: V0.5 = 4.3 ± 4.9 mV, n = 5, p = 0.2, fig. 4C) or the deactivation kinetics of Kv7.4-W242L (control:
The activating effect of SMB-1 on KV7.2 is not.

Effect of SMB-1 on channels with mutations in the refined retigabine binding site

To test if SMB-1 depends on other residues important for the action of retigabine, we generated channels where the two leucine residues (L275 and L299 in KV7.2, L281 and L305 in KV7.4) shown to be part of the binding site in KV7.3 [19] were substituted with valines, the corresponding residues in KV7.1. The resulting channels KV7.2-L275V, KV7.2-L299V, KV7.4-L281V and KV7.4-L305V were expressed in *Xenopus laevis* oocytes. We determined their $I-V$ relationship in the absence and presence of 10 μM SMB-1 (fig. 5). All channels behaved similar to the WT channels but displayed a voltage-dependence of activation that was shifted in the positive (KV7.2-L275V: $V_{0.5} = 27.7 \pm 1.1$ mV, $n = 36$ and KV7.2-L299V: $V_{0.5} = -8.7 \pm 1.3$ mV, $n = 30$) or negative (KV7.4-L305V: $V_{0.5} = -10.7 \pm 2.2$ mV, $n = 37$) direction. The L281V mutation in KV7.4 resulted in a non-functional channel. A mutation affecting this residue (L281S) has been found in patients with DFNA2 [24], indicating that it may be very critical for KV7.4 channel function.

The L275V mutation in KV7.2 affected the efficacy of SMB-1 (fig. 5A). The current amplitude was 90.4% of control at +50 mV ($n = 4$). KV7.2-L299V was inhibited to a similar degree as the WT channel (current amplitude 69.3% of control at +50 mV, $n = 4$, fig. 5B). The L305V mutation in KV7.4 abolished the effect of the compound (current amplitude 100.8±10.3% of control at +50 mV, $n = 6$, fig. 5C).

**Exposure of SMB-1 in rats**

Following subcutaneous administration of 20 mg/kg, SMB-1 was found to be rapidly absorbed systemically, and high plasma concentrations were observed (Table 1). In contrast, we found the brain exposure to be very low relative to plasma with corresponding brain/plasma partition coefficients in the range of 0.04–0.07. Considering the contribution of residual blood in the brain tissue to the brain partition coefficient, these results suggest that SMB-1 possesses limited brain penetration capabilities. In line with these findings, *in vitro* transport studies in MDCK cells showed that SMB-1 exhibited low membrane permeability of $2.5 \pm 0.3 \times 10^{-6}$ cm/s with an efflux ratio of 0.7. In addition, SMB-1 was found to be highly bound in plasma (free fraction 0.6±0.4%) and in brain homogenate (free fraction 0.1±0.1%) (mean ± S.E.M., $n = 3$).

**Discussion**

Although an increasing number of compounds has been found to activate or inhibit Kv7 channels there is still a lack of truly subtype specific drugs that can discriminate between Kv7.2–5. This has hampered the determination of the individual contribution of each subtype to the *in vivo* effects of e.g. retigabine and made it difficult to establish which subtype to target for each of the many indications where Kv7 channels have been suggested as attractive therapeutic targets.

In an attempt to develop subtype-specific Kv7 active drugs, we took advantage of previous findings that had established the so-

---

**Figure. 2. Activation of Kv7.4 by SMB-1.** (A) Representative current traces for Kv7.4 in the absence and presence of 10 μM SMB-1. (B) Effect of SMB-1 on current-voltage relationship. (C) Effect of SMB-1 on voltage-dependence of activation. (D) Effect of SMB-1 on deactivation kinetics. (E) Effect of SMB-1 on voltage-dependence of activation. Statistical significance was determined by paired, two-tailed Student’s t-test. Representative tail current traces in the absence and presence of 10 μM SMB-1 are shown in the inset. (E) Effect of SMB-1 on activation kinetics. Statistical significance was determined by two-way repeated measurements ANOVA followed by Bonferroni post-test. (F) Dose-response relationship of SMB-1 on Kv7.4. *** $p<0.001$. Bars represent S.E.M and $n=5–8$. doi:10.1371/journal.pone.0100209.g002
called retigabine binding site and the SAR of acrylamide KV7 channel compounds [11,12,19,20]. Trying to mimic the effect of a tryptophan substitution, we designed and synthesized a methylated version of (S)-2, termed SMB-1. This compound oppositely affects KV7.2 and KV7.4 channels.

SMB-1 inhibits KV7.2 by reducing the current amplitude and increasing the time constant for the slow component of the activation kinetics remarkably similar to the effects of (S)-2 on KV7.2-W236L [14]. The potency of (S)-2 on KV7.2-W236L (IC\textsubscript{50} = 8.1 μM) and SMB-1 on KV7.2 (IC\textsubscript{50} = 7.4 μM) is similar [14]. Hence, our data suggests that methylation of the amide nitrogen disables the activating component of (S)-2’s effect on KV7.2 while preserving the inhibitory component, and thereby recapitulates the pharmacological consequence of the W236L mutation.

The increase in KV7.4 current levels by SMB-1 was weak compared to the high efficacy of (S)-2 [14]. As KV7.4-W242L was inhibited by SMB-1, we speculate that the methyl-group in SMB-1 promotes an inhibitory binding mode and thereby tips the activation/inhibition equilibrium towards reduced efficacy relative to the effects of (S)-2 on KV7.4. The positive effect of SMB-1 on KV7.4 was critically dependent on the tryptophan residue in S5. Furthermore, KV7.4-L305V was SMB-1 insensitive, leading us to conclude that SMB-1 binds to the promiscuous retigabine binding site for activation of KV7.4.

In contrast, the inhibitory action of SMB-1 on KV7.2 was not critically dependent on the tryptophan residue. However, the L275V mutation in KV7.2 reduced the inhibitory efficacy of 10 μM SMB-1, indicating that it’s binding to KV7.2 also occurs within the border of this binding pocket. Since this site accommodates pan-reactive compounds, it has been suggested that it would not allow for discrimination between neuronal KV7 channel subtypes [25]. These findings demonstrate that this binding site can indeed accommodate compounds that oppositely affect neuronal KV7 channels thereby giving rise to subtype selectivity. To further examine the basis of the opposite effect of SMB-1 on KV7.2 and KV7.4 in more detail, a cross-mutational approach may be applied where non-conserved residues within the binding pocket are swapped between the two subtypes.

What may this compound be used for? Foremost, determining the contribution of different KV7 channel subtypes to currents in various regions may assign particular physiological functions to particular subtypes.

Compounds modulating KV7 channels may have a therapeutic potential in relation to schizophrenia. This disease is characterized by psychotic or positive symptoms such as hallucinations, delusions, thought disorder, disorganized speech and paranoia; negative symptoms, which include lack of mental activities such as thoughts and motivation; and cognitive symptoms comprising failure of working memory, impairments of learning and attentional dysfunction [26]. According to the dopamine hypothesis of schizophrenia the positive symptoms result from over-active neurotransmission in the mesolimbic dopamine pathway [27,28]. This hypothesis is based on the fact that antipsychotic drugs work by blocking dopamine D\textsubscript{2} receptors, while compounds that increase dopamine levels can induce psychosis or exacerbate schizophrenia [27,29]. On the other hand, a hypodopaminergic state in the frontal cortical terminal fields of the mesocortical dopamine neurons is thought to underlie the negative and cognitive symptoms [28]. The antipsychotic drugs available on

Figure 3. Effect of SMB-1 on KV7.2-W236L. (A) Representative current traces for KV7.2-W236L in the absence and presence of 10 μM SMB-1 (B) Effect of SMB-1 on current-voltage relationship. (C) Effect of SMB-1 on voltage-dependence of activation. (D) Effect of SMB-1 on deactivation kinetics. Statistical significance was determined by paired, two-tailed Student’s t-test. Representative tail current traces in the absence and presence of 10 μM SMB-1 are shown in the inset. Effect of SMB-1 on the fast (E) and slow (F) component of the activation kinetics. Statistical significance was determined by two-way repeated measurements ANOVA followed by Bonferroni post-test. Y-values were log-transformed before the statistical analysis to meet the assumption of normality. * p<0.05, ** p<0.01, *** p<0.001. Bars represent S.E.M and n = 4–6.

doi:10.1371/journal.pone.0100209.g003
the market today are more or less efficient in ameliorating the positive symptoms but have little or no effect on the negative and cognitive symptoms. Compounds with differential modulatory action across the Kv7 channel family could aid in determining the most optimal subtype profile.

Kv7 channel inhibitors were initially developed as cognition enhancers based on their ability to increase acetylcholine release [30,31,32]. This effect probably stems from inhibition of Kv7.2 and Kv7.2/3 channels as the reference inhibitor XE-991 has been shown to more potently inhibit Kv7.2 and Kv7.2/3 than Kv7.4 channels albeit the data are reported from different laboratories [1,33]. Kv7 channels also play a role in the dopaminergic system and retigabine has anti-dopaminergic effects in the basal ganglia [9,34,35,36]. Kv7.4 has been suggested as the subtype mediating the efficacy of pan-reactive Kv7 channel openers in modulation of the dopaminergic system [9,35,36]. Hence, we speculate that a

Figure 4. Effect of SMB-1 on Kv7.4-W242L. (A) Representative current traces for Kv7.4-W242L in the absence and presence of 10 μM SMB-1. (B) Effect of SMB-1 on current-voltage relationship. (C) Effect of SMB-1 on voltage-dependence of activation. (D) Effect of SMB-1 on deactivation kinetics. Statistical significance was determined by paired, two-tailed Student’s t-test. Representative tail current traces in the absence and presence of 10 μM SMB-1 are shown in the inset (note that the traces are completely overlapping). (E) Effect of SMB-1 on activation kinetics. Statistical significance was determined by two-way repeated measurements ANOVA followed by Bonferroni post-test. Bars represent S.E.M and n = 5.

doi:10.1371/journal.pone.0100209.g004

Figure 5. Effect of SMB-1 on channels with mutations in the refined retigabine binding site. Effect of 10 μM SMB-1 on the current-voltage relationship of (A) Kv7.2-L275V, (B) Kv7.2-L299V and (C) Kv7.4-L305V. Bars represent S.E.M. and n = 4–6.

doi:10.1371/journal.pone.0100209.g005
balanced inhibition of Kv7.2 and Kv7.2/3 in combination with enhancement of Kv7.4 current may be efficacious with respect to targeting of both positive and cognitive symptoms in patients suffering from schizophrenia. As this is hypothetical, proof of this concept necessitates an evaluation of SMB-1 in animal models of psychosis and cognition. Unfortunately, even though SMB-1 was not identified as a substrate for the efflux transporter P-gp judged from the efflux ratio in MDR1-MDCK cells, we found it to have low membrane permeability with poor CNS distribution in rats limiting its in vivo pharmacological potential after systemic administration in the CNS. However, the recent years have provided evidence for a role of the so-called neuronal Kv7 channels in the vasculature [37,38,39]. Kv7.4 channels in vivo have vasorelaxant effects which could in turn have an impact on cerebral circulation.

In conclusion, we have identified a novel Kv7 channel active compound with a unique characteristic in that it inhibits Kv7.2 but activates Kv7.4. SMB-1 provides valuable insight into the pharmacology of Kv7 channels and may be used as a template for the further design of better subtype selective Kv7 channel modulators.

**Author Contributions**

Conceived and designed the experiments: SMB MR JK CB HSJ. Performed the experiments: SMB MR JK CB. Analyzed the data: SMB CB. Contributed reagents/materials/analysis tools: NS. Wrote the paper: SMB MR JK CB NS HSJ.

**References**

1. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, et al. (1998) KCNQ2 and KCNQ3 Potassium Channel Subunits: Molecular Correlates of the M-Channel. Science 282: 1890–1893.
2. Jenschn TJ (2000) Neuronal KCNQ potassium channel physiology and role in disease. Nat Rev Neurosci 1: 21–30.
3. Brown DA, Adams PR (1980) Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature 283: 673–676.
4. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, et al. (1998) A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 18: 25–29.
5. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, et al. (1998) A Potassium Channel Mutation in Neonatal Human Epilepsy. Science 279: 493–496.
6. Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, et al. (1998) A pore mutation in a novel IQK1-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 18: 53–55.
7. Blackburn-Munro G, Jenssen BS (2003) The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 460: 109–116.
8. Wu YJ, Boissard CG, Grecco A, Grimböck KV, Harden DG, et al. (2003) (S)-N-[1-(3-Morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: An Orally Bioavailable KCNQ2 Opener with Significant Activity in a Cortical Spreading Depression Model of Migraine. J Med Chem 46: 3197–3200.
9. Hansen HH, Ebbesen C, Mathiesen C, Weikop P, Ronn LC, et al. (2006) The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Eur J Pharmacol 460: 109–116.
10. Korsgaard MPG, Hartz BP, Brown WD, Ahring PK, Strobaek D, et al. (2005) Retigabine Inhibits the Activity of Mesencephalic Dopaminergic Systems of the Rat. J Pharmacol Exp Ther 314: 282–292.
11. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, et al. (1998) KCNQ2 and KCNQ3 Potassium Channel Subunits: Molecular Correlates of the M-Channel. Science 282: 1890–1893.
12. Mueser KT, McGurk SR (2004) Schizophrenia. Lancet 363: 2063–2072.
13. Bentzen BH, Schmitt N, Calloe K, Dalby-Brown W, Grunnet M, et al. (2006) Novel Potassium Channel Modulator ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett 406: 109–116.
14. Padilla K, Wickenden AD, Gerlach AC, McCormack K (2009) The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett 465: 138–142.
15. Blom SM, Schmitz N, Jensen HS (2010) Differential effects of ICA-27243 on cloned Kv7.4 channels. Pharmacology 86: 174–181.
16. Xiao Q, Sun H, Zhang Y, Nan F, Li M (2008) Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers. Proc Natl Acad Sci U S A 105: 3126–3131.
17. Padilla K, Wickenden AD, Gerlach AC, McCormack K (2009) The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett 465: 138–142.
18. Miers F, Soldovieri MV, Martire M, Tagliatela M (2008) Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. Curr Opin Pharmacol 8: 65–74.
19. Lange W, Geissendorfer J, Schenzer A, Grotzinger J, Sekhoban G, et al. (2009) Riluzole and Structure-Activity Relationship of Acrylamides as KCNQ2 Potassium Channel Openers. J Med Chem 47: 275–280.
20. Wu YJ, He H, Sun LZ, I·Heurux C, Chen J, et al. (2004) Synthesis and Refinement of the Binding Site and Mode of Action of the Anticonvulsant retigabine on KCNQ2+3 Channels. Mol Pharmacol 73: 272–280.
21. Risgaard R, Ettrup A, Balle T, Dysegaard A, Hansen HD, et al. (2013) Radiolabeling and PET brain imaging of the 9(1-adrenoceptor antagonist Lu AE49396. Nuclear medicine and biology 40: 150–154.
22. Redrobe JP, Elster L, Frederiksen K, Bundgaard C, Jong EM, et al. (2011) Negative modulation of GABAA receptors by RO4938011 attenuates discrete sub-chronic and early postnatal phenylalanine (KCP)-induced cognitive deficits in rats. Psychopharmacology 221: 431–468.
23. Wu YJ, Boissard CG, Chen J, Fitzpatrick W, Gao Q, et al. (2004) (S)-N-[1-(4-Cyclopropylmethyl)-3,4-dihydro-2H-benzof[b][1,4]benzoxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons. Bioorg Med Chem Lett 14: 1991–1995.
24. Talebizadeh Z, Kelley PM, Asker JW, Beisel KW, Smith SD (1999) Novel mutation in the KCNQ1 gene in a large kindred with dominant progressive hearing loss. Hum Mutat 14: 493–501.
25. Grimbök KV (2008) The therapeutic potential of neuronal Kv7 (KCNQ) channel modulators: an update. Expert Opin Ther Tar 12: 563–571.
26. Mueser KT, McGurk SR (2004) Schizophrenia. Lancet 363: 2063–2072.
27. Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1: 133–152.
28. Duncan GE, Shostman BB, Lieberman JA (1999) An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 29: 250–264.
29. Lieberman JA, Kane JM, Abir J (1987) Provocative tests with psychostimulant drugs in schizophrenia. Psychophysiology 16: 415–433.
30. Nickolson VJ, Tam SW, Myers MJ, Cook L (1990) Du P 996 (3,3-Bis(4-pyrindinylmethyl)-1-Phenylindolin-2-One) Enhances the StimulIus induced Release of Acetylcholine From Rat Brain In Vitro and In Vivo. Drug Dev Res 19: 285–300.
31. Cook L, Nickolson VJ, Steinfelds GF, Rohrbach KW, Denoble VJ (1990) Cognition enhancement by the acetylcholine releaser DuP 996. Drug Dev Res 19: 301–314.
32. Aiken SP, Lampe BJ, Murphy PA, Brown BS (1995) Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer. Br J Pharmacol 115: 1163–1168.

33. Søgaard R, Ljungstrom T, Pedersen KA, Olsen SP, Jensen BS (2001) KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. Am J Physiol Cell Physiol 280: C359–866.

34. Sotty F, Damgaard T, Monteirinho LP, Mork A, Olsen CK, et al. (2009) Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission. J Pharmacol Exp Ther 328: 951–962.

35. Hansen HH, Andreasen JT, Weikop P, Mirza N, Scheel-Kruger J, et al. (2007) The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol 570: 77–88.

36. Hansen HH, Waroux O, Neutin V, Jentsch TJ, Aznar S, et al. (2008) Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS. J Physiol 586: 1823–1832.

37. Mackie AR, Byron KL (2008) Cardiovascular KCNQ (Kv7) Potassium Channels: Physiological Regulators and New Targets for Therapeutic Intervention. Molecular Pharmacology 74: 1171–1179.

38. Greenwood IA, Ohya S (2009) New tricks for old dogs: KCNQ expression and role in smooth muscle. British Journal of Pharmacology 156: 1196–1203.

39. Stott JB, Jepps TA, Greenwood IA (2013) Kv7 potassium channels: a new therapeutic target in smooth muscle disorders. Drug Discov Today.

40. Chadha PS, Jepps TA, Carr G, Stott JB, Zhu H-L, et al. (2014) Contribution of Kv7.4/Kv7.5 Heteromers to Intrinsic and Calcitonin Gene-Related Peptide-Induced Gerebral Reactivity. Arteriosclerosis, Thrombosis, and Vascular Biology 34: 887–893.

41. Khanamiri S, Solhysinska E, Jepps TA, Bentzen BH, Chadha PS, et al. (2015) Contribution of Kv7 Channels to Basal Coronary Flow and Active Response to Ischemia. Hypertension 62: 1090–1097.

42. Chadha PS, Zunke F, Zhu H-L, Davis AJ, Jepps TA, et al. (2012) Reduced KCNQ4-Encoded Voltage-Dependent Potassium Channel Activity Underlies Impaired β-Adrenoceptor-Mediated Relaxation of Renal Arteries in Hypertension. Hypertension 59: 877–884.